AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00839332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00456378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAM™ Spinal Stabilization System
Description: Surgical procedure with implantation of the Investigational device
Study NCT00456378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative care
Description: Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
Study NCT03722498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of FOLFOX
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT03722498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: administration of Sorafenib
Study NCT03260803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligopin
Description: Oligopin ,150 mg ,once daily, 12 week
Study NCT03260803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,150 mg ,once daily, 12 week
Study NCT01226836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LWWCOPD for Pulmonary Rehabilitation
Description: As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
Study NCT01108042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
Description: Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
Study NCT02062645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine/valsartan
Description: Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
Study NCT01376297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant and Palonosetron
Study NCT01376297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Study NCT01376297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Study NCT01376297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT01376297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00087555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (sodium oxybate) oral solution
Description: Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
Study NCT00087555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (sodium oxybate) oral solution
Description: Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
Study NCT00087555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one of two doses matching active treatment by volume for 8 weeks.
Study NCT01113164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron and Sertraline
Description: capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
Study NCT00582114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
Study NCT00582114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
Study NCT00461123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Study NCT00461123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Study NCT01233271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Study NCT04186052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CART cells
Description: Target BCMA chimeric antigen receptor T cell infusion
Study NCT04514172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive industrial exoskeleton for back support
Description: The goal is to compare the human response to the simulated industrial tasks
Study NCT00694720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules once a day at bedtime
Study NCT01486186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
Study NCT01486186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo chinese medicine
Description: There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
Study NCT00766844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation
Description: electrode is inserted into cervical epidural space for continuous spinal cord stimulation
Study NCT03341117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 300 mg per capsule
Study NCT03341117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcined magnesia
Description: Calcined magnesia 300 mg per capsule
Study NCT03737279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Routine care + twice daily meditation per schedule, to start on the day of randomization
Study NCT03737279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy
Study NCT03737279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy
Study NCT02537652 — intervention group
Intervention type: OTHER
Intervention: Blood pressure assessment
Description: Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
Study NCT01118988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
Study NCT03353948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
Study NCT03353948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBI
Description: In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
Study NCT01337323 — intervention group
Intervention type: DRUG
Intervention: Fluticasone furoate nasal spray
Description: fluticasone furorate intranasal steroid spray
Study NCT03737266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonographically assisted breast surgery
Description: Sonography
Study NCT03737266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonographically assisted breast surgery
Description: Sonography
Study NCT03737266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional breast surgery
Description: Conventional
Study NCT03737266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional breast surgery
Description: Conventional
Study NCT00926640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
Study NCT00926640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 cycles at 60mg/m2 IV on day 2
Study NCT04514172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The protocol will be performed without exoskeleton
Description: The protocol will be performed without exoskeleton
Study NCT02901483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP503
Description: PEP503 will be administered by intratumoral route as slow injection
Study NCT02901483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.
Study NCT02901483 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
Study NCT01691547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC /VI
Description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
Study NCT01691547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
Study NCT01691547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
Study NCT01691547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
Study NCT04241887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral blockade
Description: Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
Study NCT04241887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthesia
Description: Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
Study NCT03880825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin 500 mg Oral Tablet
Description: single dose
Study NCT03880825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levoketoconazole 150 - 600 mg (BID)
Description: escalating dose from 150 mg to 600 mg (BID)
Study NCT04865614 — intervention group
Intervention type: DRUG
Intervention: Etomidate
Description: Use of etomidate
Study NCT04865614 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Use of sevoflurane
Study NCT03796208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)
Description: Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
Study NCT03796208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
Study NCT00953511 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: ERCC1 pathways analysis
Description: The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
Study NCT03271918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Study NCT01161628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
Study NCT04363710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet
Description: 800-1000 Kcal/day
Study NCT02383407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Deep Brain Stimulation
Study NCT05076136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional treatment
Description: In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
Study NCT05076136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy treatment
Description: In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
Study NCT01975636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
Study NCT02860299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citrate 4%
Study NCT02860299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Study NCT02860299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02860299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Study NCT04865510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional citrate anticoagulation
Description: The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6).
Study NCT04865510 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Regional citrate anticoagulation
Description: The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6).
Study NCT03185702 — intervention group
Intervention type: GENETIC
Intervention: Research genetic tests
Description: DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
Study NCT03536702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Writing Workshop
Description: This group will participate in a writing workshop in group sessions.
Study NCT03536702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Independent Writing - Control Group
Description: This group will receive a book for a self writing session.
Study NCT02724293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabaline 300 mg once.
Description: patients received pregabaline 300 mg 2 hours pre-operatively.
Study NCT02724293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabaline 300 mg twice.
Description: patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
Study NCT02724293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabaline 600 mg once.
Description: patients received pregabaline 600 mg 2 hours pre-operatively.
Study NCT02724293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received placebo
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Vincristine in induction
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Daunorubicin in induction
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Prednisone in induction
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Metotrexato in induction